Valuation dashboard for DexCom, Inc. (DXCM) with P/E 32.27, P/B 12.16, EV/EBITDA 20.07 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners.
Analysis Summary
DexCom, Inc. reported revenue of $4.66B in the most recent fiscal year, growing at a 5-year CAGR of 19.3%. Net income reached $836.3M, with a 11.1% 5-year CAGR.
Trailing-twelve-month margins: gross margin 63.4%, operating margin 24.0%, net margin 19.4%.
At $82.29 (closing price, October 30, 2026), DXCM trades at a P/E of 32.27 and an ROE of 36.50%. Market capitalisation stands at $30.7B, placing it among large-cap names.
Balance sheet quality for DXCM: current ratio of 1.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 32.27 |
| Price / Book | 12.16 |
| EV / EBITDA | 20.07 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $42.16 |
| vs Current Price | -48.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DXCM | DexCom, Inc. | $30.7B | 32.27 | 12.16 | 36.5% |
| PODD | Insulet Corp. | $10.4B | 27.98 | 7.29 | 26.7% |
| MMED | MiniMed Group, Inc. | $5.1B | 1.42 | -9.1% | |
| ABT | Abbott Laboratories | $183.8B | 39.33 | 3.61 | 9.1% |
| 0Y6X.L | Medtronic Plc | $124.4B | 23.33 | 2.43 | 10.6% |
| MDT | Medtronic Plc | $123.5B | 23.78 | 2.46 | 10.6% |
| SYK | Stryker Corporation | $111.9B | 31.08 | 4.76 | 15.6% |
| 0R2S.L | Stryker Corporation | $111.1B | 31.57 | 4.91 | 16.4% |
Price
| Price | $82.29 (closing price, October 30, 2026) |
| Market Cap | $30.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 36.50% |
| Return on Invested Capital | 23.98% |
| Return on Assets | 15.88% |
| Gross Margin | 63.42% |
| Operating Margin | 23.98% |
| Net Margin | 19.41% |
Related companies: PODD · MMED · ABT · 0Y6X.L · MDT · SYK · 0R2S.L · 0HOY.L
Explore sector: Healthcare · Medical - Devices
More sections of DXCM: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks